| Literature DB >> 34164345 |
Magda Melissa Flórez1, Rocío Rodríguez2, José Antonio Cabrera3, Sara M Robledo4, Gabriela Delgado1.
Abstract
Vaccines are one of the most effective strategies to fight infectious diseases. Reverse vaccinology strategies provide tools to perform in silico screening and a rational selection of potential candidates on a large scale before reaching in vitro and in vivo evaluations. Leishmania infection in humans produces clinical symptoms in some individuals, while another part of the population is naturally resistant (asymptomatic course) to the disease, and therefore their immune response controls parasite replication. By the identification of epitopes directly in humans, especially in those resistant to the disease, the probabilities of designing an effective vaccine are higher. The aim of this work was the identification of Leishmania epitopes in resistant humans. To achieve that, 11 peptide sequences (from Leishmania antigenic proteins) were selected using epitope prediction tools, and then, peripheral blood mononuclear cells (PBMCs) were isolated from human volunteers who were previously divided into four clinical groups: susceptible, resistant, exposed and not exposed to the parasite. The induction of inflammatory cytokines and lymphoproliferation was assessed using monocyte-derived dendritic cells (moDCs) as antigen-presenting cells (APCs). The response was evaluated after exposing volunteers' cells to each peptide. As a result, we learned that STI41 and STI46 peptides induced IL-8 and IL-12 in moDCs and lymphoproliferation and low levels of IL-10 in lymphocytes differentially in resistant volunteers, similar behavior to that observed in those individuals to L. panamensis lysate antigens. We conclude that, in silico analysis allowed for the identification of natural Leishmania epitopes in humans, and also STI41 and STI46 peptides could be epitopes that lead to a cellular immune response directed at parasite control.Entities:
Keywords: T epitopes; humans; leishmaniasis; naturally resistant; reverse vaccinology; synthetic peptides
Year: 2021 PMID: 34164345 PMCID: PMC8216392 DOI: 10.3389/fcimb.2021.631019
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
In silico analysis of binding prediction to HLA-DR alleles.
| Protein | Code | Sequence | Prediction tool | Identity between | Homology (%) with human protein | Identity (%) with T. cruzi sequence** | ||
|---|---|---|---|---|---|---|---|---|
| IEDB‡ | NETMHCIIpan‡ | TepitopePan‡ | ||||||
|
| LACK08 | LEGHTGFVSCVSLAH | 04:01, 04:04, 04:10, 11:01, 11:02, 13:05. | NB | 04:01, 04:05, 04:07, 10:01. | 100% | NO (33%) | 60% |
|
| STI72 | GRYVEAVNYFSKAIQ | 11:02, 11:01, 13:01, 13:04. | NB | 11:02, 13:04. | 100% | NO (33%) | 60% |
| STI40 | NWAKGYVRRGAALHG | 01:02, 11:01, 13:04. | NB | 08:02, 08:03. | 100% | NO (53%) | 80% | |
| STI41 | KLSLLMLQPDYVKMV | 01:02, 01:03, 03:01, 04:03, 04:04, 04:06, 04:11, 10:01, 15:01, | 01:02, 04:03, 04:04, 04:06, 04:10, 04:11, 08:03, 12:01, 14:01, 15:01, | NB | 100% | NO (20%) | 73.3% | |
| STI42 | ALTLMYLSGMKIPND | 01:01, 01:02, 04:04, 11:01, 13:05, 15:01. | 15:01. | 01:02, 01:03. | 100% | NO (27%) | 46.6% | |
| STI43 | TLYILNVSAVYFEQR | 01:01, 01:02, 03:01, 04:10, 11:02, 12:01, 13:01, 13:02, | 01:03, 04:07, 08:03, 13:02, 13:03, 14:02, 16:02. | NB | *93% | NO (53%) | 53.3% | |
| STI44 | YTIVAKLMTRHAFCL | 08:03, 11:01, 11:02, 12:02, 13:03, 13:05, 14:01, 14:02, 16:02. | 01:02, 04:04, 04:10, 04:11, 08:02, 11:01, 11:02, 12:01, 12:02, 13:01, 13:04, 13:05, 14:01. | NB | *80% | NO (33%) | 73.3% | |
| STI46 | SVKINKLISAGIIRF | 01:03, 01:02, 03:01, 04:03, 04:04, 04:06, 04:11, 07:01, 08:02.10:01, 11:01, 11:02, 13:03, 14:01, 15:01. | 01:01, 01:02, 01:03, 04:07, 07:01, 08:03, 11:02, 12:01, 13:01, 13:04, 14:01, 15:01. | NB | *93% | NO (40%) | 80% | |
|
| LEIF73 | FSIGLLQRLDFRHNL | 13:05, 13:01, 11:01, 03:01, 13:04. | 12:02. | 12:02, 13:05. | 100% | NO (47%) | 93.3% |
| LEIF50 | YEIFRFLPKDIQVAL | 01:02, 11:01, 11:02, 13:01, 13:04. | 12:02. | 13:03, 14:02. | 100% | NO (47%) | 86.6% | |
| LEIF52 | QSVIFANTRRKVDWI | 08:03, 11:01, 11:02, 13:03, 13:01, 14:01, 14:02, | 11:01, 11:02, 13:01, 13:03, 13:04, 13:05. | NB | 100% | NO (73%) | 93.3% | |
‡Alleles with predicted strong binding to the sequence.
*Sequences with amino acids substitution for another with similar characteristics.
L. panamensis, L. braziliensis, and L. major species.
NB, Non-binders.
**Trypanosoma cruzi strain CL Brener.
Classification of human volunteers.
| Clinical group | Characteristics | n | Parasitological diagnosis | Leishmanin Skin Test (LST) | Gender* | Age in years old: mean (range) |
|---|---|---|---|---|---|---|
|
| Affected by the disease | 10 | Confirmed | Positive | F:7M:3 | 44.1 (12-81) |
|
| No disease history | 10 | No lesions | Positive | F:6M:4 | 29.5 (18-55) |
|
| Living in endemic areas | 14 | No lesions | Negative | F:6M:8 | 47.6 (13-88) |
|
| Living in non-endemic areas | 11 | No lesions | Negative | F:7M:4 | 31.4 (23-57) |
|
| 45 | F:26M:19 | 38.45 (12-88) |
*F, female; M, male.
Figure 1Cytokines detected in human moDCs supernatants from S (susceptible), R (resistant), E (exposed), and NE (not exposed) groups. Cell pulsed with (A) peptides derived from LACK protein; (B) peptides derived from STI1 protein; (C) peptides derived from LEIF, and (D) L. panamensis or PHA. P<0.05(*), P<0.01(**). Dashed line: non-stimulated cell response.
Figure 2Proliferation Index (PI) evaluated in S (susceptible), R (resistant), E (exposed), and NE (not exposed) groups. Cells response to (A) peptides derived from LACK protein; (B) peptides derived from STI1 protein; (C) peptides derived from LEIF, and (D) L. panamensis or PHA. p<0.05(*), P<0.01(**), P<0.001(***). Dashed line: non-stimulated cell response.
Figure 3Division Index (DI) evaluated in S (susceptible), R (resistant), E (exposed), and NE (not exposed) groups. Cells response to (A) peptides derived from LACK protein; (B) peptides derived from STI1 protein; (C) peptides derived from LEIF, and (D) L. panamensis or PHA. p<0.05(*), P<0.01(**), P<0.001(***). Dashed line: non-stimulated cell response.
Figure 4Cytokines from lymphocytes detected in culture supernatants in S (susceptible), R (resistant), E (exposed), and NE (not exposed) groups. Cell exposed to (A) Pre-selected peptides and (B) L. panamensis or PHA. p<0.05(*), P<0.01(**). Dashed line: non-stimulated cells response.